Mitochondrial ADP/ATP exchange inhibition: A novel off-Target mechanism underlying ibipinabant-induced myotoxicity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Schirris, Tom J J ^a   Ritschel, Tina ^a   Herma Renkema, G ^a   Willems, Peter H G M ^a   Smeitink, Jan A M ^a   Russel, Frans G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMIDINE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; IBIPINABANT; MULTIENZYME COMPLEX; PYRAZOLE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; CYTOLOGY; DOG; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MITOCHONDRION; MOUSE; MYOBLAST; OBESITY; OXYGEN CONSUMPTION; PATHOLOGY; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMIDINES; ANIMALS; ANTI-OBESITY AGENTS; CANNABINOID RECEPTOR ANTAGONISTS; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HUMANS; MICE; MITOCHONDRIA; MITOCHONDRIAL ADP, ATP TRANSLOCASES; MUSCLE, SKELETAL; MYOBLASTS; OBESITY; OXYGEN CONSUMPTION; PYRAZOLES; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84942627515     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14533     Document Type: Article

References (48)

1. Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384, 766-781, doi: 10.1016/S0140-6736(14)60460-8 (2014).
2. Di Marzo, V. & Despres, J. P. CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nature reviews. Endocrinology 5, 633-638, doi: 10.1038/nrendo.2009.197 (2009).
3. Silvestri, C. & Di Marzo, V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert opinion on investigational drugs 21, 1309-1322, doi: 10.1517/13543784.2012.704019 (2012).
4. Silvestri, C., Ligresti, A. & Di Marzo, V. Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle. Reviews in endocrine & metabolic disorders 12, 153-162, doi: 10.1007/s11154-011-9167-3 (2011).
5. Andre, A. & Gonthier, M. P. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. The international journal of biochemistry & cell biology 42, 1788-1801, doi: 10.1016/j.biocel.2010.06.002 (2010).
6. Silvestri, C. & Di Marzo, V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell metabolism 17, 475-490, doi: 10.1016/j.cmet.2013.03.001 (2013).
7. Kunos, G. & Tam, J. The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. British journal of pharmacology 163, 1423-1431, doi: 10.1111/j.1476-5381.2011.01352.x (2011).
8. Sharma, M. K., Murumkar, P. R., Kanhed, A. M., Giridhar, R. & Yadav, M. R. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. European journal of medicinal chemistry 79, 298-339, doi: 10.1016/j.ejmech.2014.04.011 (2014).
9. Van Gaal, L. F. et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-1397, doi: 10.1016/S0140-6736(05)66374-X (2005).
10. FDA. FDA briefing document NDA 21-888: Zimulti (rimonabant) Tablets 20 mg. Saofi-Aventis Advisory Committee, 2007).
11. Chorvat, R. J. Peripherally restricted CB1 receptor blockers. Bioorganic & medicinal chemistry letters 23, 4751-4760, doi: 10.1016/j.bmcl.2013.06.066 (2013).
12. Tam, J. et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell metabolism 16, 167-179, doi: 10.1016/j.cmet.2012.07.002 (2012).
13. Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825, doi: 10.1038/35071088 (2001).
14. Wilson, C. Obesity: CB1R inverse agonists-Antiobesity effects without the neuropsychiatric adverse effects? Nature reviews. Endocrinology 8, 564, doi: 10.1038/nrendo.2012.145 (2012).
15. Tomlinson, L. et al. Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-Adipic aciduria in beagle dogs. Toxicological sciences: An official journal of the Society of Toxicology 129, 268-279, doi: 10.1093/toxsci/kfs217 (2012).
16. Wallace, K. B. & Starkov, A. A. Mitochondrial targets of drug toxicity. Annual review of pharmacology and toxicology 40, 353-388, doi: 10.1146/annurev.pharmtox.40.1.353 (2000).
17. Wood, D. J., de Vlieg, J., Wagener, M. & Ritschel, T. Pharmacophore fingerprint-based approach to binding site subpocket similarity and its application to bioisostere replacement. Journal of chemical information and modeling 52, 2031-2043, doi: 10.1021/ci3000776 (2012).
18. Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res 28, 235-242, doi: 10.1093/nar/28.1.235 (2000).
19. Kedrov, A. et al. Probing the interactions of carboxy-Atractyloside and atractyloside with the yeast mitochondrial ADP/ATP carrier. Structure 18, 39-46, doi: 10.1016/j.str.2009.11.009 (2010).
20. Vyssokikh, M. Y. & Brdiczka, D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta biochimica Polonica 50, 389-404, doi: 035002389 (2003).
21. Skulachev, V. P. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis: An international journal on programmed cell death 11, 473-485, doi: 10.1007/s10495-006-5881-9 (2006).
22. Acevedo, L. M. & Rivero, J. L. New insights into skeletal muscle fibre types in the dog with particular focus towards hybrid myosin phenotypes. Cell and tissue research 323, 283-303, doi: 10.1007/s00441-005-0057-4 (2006).
23. Iannotti, F. A. et al. The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels. Proceedings of the National Academy of Sciences of the United States of America 111, E2472-2481, doi: 10.1073/pnas.1406728111 (2014).
24. Benard, G. et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nature neuroscience 15, 558-564, doi: 10.1038/nn.3053 (2012).
25. Fisar, Z., Singh, N. & Hroudova, J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicology letters 231, 62-71, doi: 10.1016/j.toxlet.2014.09.002 (2014).
26. Tedesco, L. et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: The role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 59, 2826-2836, doi: 10.2337/db09-1881 (2010).
27. Chorvat, R. J., Berbaum, J., Seriacki, K. & McElroy, J. F. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorganic & medicinal chemistry letters 22, 6173-6180, doi: 10.1016/j.bmcl.2012.08.004 (2012).
28. Maldonado, E. N. & Lemasters, J. J. ATP/ADP ratio, the missed connection between mitochondria and the Warburg effect. Mitochondrion 19 Pt A, 78-84, doi: 10.1016/j.mito.2014.09.002 (2014).
29. Liu, Y. & Chen, X. J. Adenine nucleotide translocase, mitochondrial stress, and degenerative cell death. Oxidative medicine and cellular longevity 2013, 146860, doi: 10.1155/2013/146860 (2013).
30. Rasola, A. & Bernardi, P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis: An international journal on programmed cell death 12, 815-833, doi: 10.1007/s10495-007-0723-y (2007).
31. Wittgen, H. G. et al. Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. Molecular pharmaceutics 9, 1351-1360, doi: 10.1021/mp200617z (2012).
32. Wittgen, H. G. et al. Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-Associated proteins MRP1, MRP2, MRP3, and MRP4. Drug metabolism and disposition: The biological fate of chemicals 39, 1294-1302, doi: 10.1124/dmd.110.037812 (2011).
33. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome biology 7, R100, doi: 10.1186/gb-2006-7-10-r100 (2006).
34. Janssen, A. J., Smeitink, J. A. & van den Heuvel, L. P. Some practical aspects of providing a diagnostic service for respiratory chain defects. Annals of clinical biochemistry 40, 3-8, doi: 10.1258/000456303321016114 (2003).
35. Janssen, A. J. et al. Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. Clinical chemistry 52, 860-871, doi: 10.1373/clinchem.2005.062414 (2006).
36. Renkema, G. H. et al. SDHA mutations causing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors. European journal of human genetics: EJHG 23, 202-209, doi: 10.1038/ejhg.2014.80 (2014).
37. Kuznetsov, A. V. et al. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nature protocols 3, 965-976, doi: 10.1038/nprot.2008.61 (2008).
38. Ferecatu, I. et al. Evidence for a mitochondrial localization of the retinoblastoma protein. BMC cell biology 10, 50, doi: 10.1186/1471-2121-10-50 (2009).
39. Janssen, A. J. et al. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. Clinical chemistry 53, 729-734, doi: 10.1373/clinchem.2006.078873 (2007).
40. Mourmans, J. et al. Clinical heterogeneity in respiratory chain complex III deficiency in childhood. Journal of the neurological sciences 149, 111-117, doi: 10.1016/S0022-510X(97)05379-3 (1997).
41. Rodenburg, R. J. Biochemical diagnosis of mitochondrial disorders. Journal of inherited metabolic disease 34, 283-292, doi: 10.1007/s10545-010-9081-y (2011).
42. Distelmaier, F. et al. Life cell quantification of mitochondrial membrane potential at the single organelle level. Cytometry. Part A: The journal of the International Society for Analytical Cytology 73, 129-138, doi: 10.1002/cyto.a.20503 (2008).
43. Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA-A selfparameterizing force field. Proteins 47, 393-402, doi: 10.1002/prot.10104 (2002).
44. Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855, doi: 10.1126/science.1215904 (2012).
45. Berman, H. M., J. W., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. & Bourne, P. E. The Protein Data Bank. Nucleic Acids Research 28, 235-242 (2000).
46. Nury, H. et al. Structural basis for lipid-mediated interactions between mitochondrial ADP/ATP carrier monomers. FEBS letters 579, 6031-6036, doi: 10.1016/j.febslet.2005.09.061 (2005).
47. Vander Heiden, M. G., Chandel, N. S., Schumacker, P. T. & Thompson, C. B. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Molecular cell 3, 159-167, doi: 10.1016/S1097-2765(00)80307-X (1999).
48. Zhang, Y., Soboloff, J., Zhu, Z. & Berger, S. A. Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen speciesinduced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Molecular pharmacology 70, 1424-1434, doi: 10.1124/mol.106.024323 (2006).